While investors are bracing for yet another challenging quarter when earnings season kicks off for commercial-stage biopharma later this month, Barclays has picked Eli Lilly (NYSE:LLY) and Merck (NYSE:MRK) as two of the most favorably positioned big pharma stocks heading into the Q2 earnings season.
Barclays Q2 2023 earnings preview on biopharma comes at a time when healthcare has become a notable laggard in the S&P 500 this year: Pharmaceutical companies in the benchmark index have lost ~5% YTD.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased